Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 8 | 2018 | 2209 | 0.97 | Why? |
| HIV Infections | 14 | 2018 | 11620 | 0.70 | Why? |
| Cyclohexanes | 1 | 2017 | 43 | 0.69 | Why? |
| Drugs, Investigational | 2 | 2018 | 198 | 0.67 | Why? |
| HIV Fusion Inhibitors | 1 | 2017 | 80 | 0.66 | Why? |
| Triazoles | 1 | 2017 | 440 | 0.50 | Why? |
| Pre-Exposure Prophylaxis | 2 | 2018 | 1138 | 0.45 | Why? |
| Reverse Transcriptase Inhibitors | 3 | 2018 | 309 | 0.41 | Why? |
| Drug Discovery | 3 | 2018 | 3092 | 0.34 | Why? |
| HIV Antibodies | 3 | 2018 | 776 | 0.34 | Why? |
| HIV-1 | 7 | 2018 | 3365 | 0.32 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 952 | 0.27 | Why? |
| Viremia | 3 | 2018 | 1020 | 0.23 | Why? |
| New York City | 5 | 2020 | 7432 | 0.22 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.21 | Why? |
| Neurotransmitter Transport Proteins | 1 | 2018 | 1 | 0.19 | Why? |
| Receptors, Neurotransmitter | 1 | 2018 | 10 | 0.19 | Why? |
| Phosphotransferases | 1 | 2018 | 16 | 0.19 | Why? |
| Deoxyadenosines | 1 | 2018 | 12 | 0.19 | Why? |
| HIV Protease Inhibitors | 1 | 2002 | 434 | 0.18 | Why? |
| Benzoxazines | 1 | 2018 | 103 | 0.18 | Why? |
| HIV | 2 | 2018 | 1116 | 0.17 | Why? |
| Piperazines | 2 | 2012 | 445 | 0.17 | Why? |
| Patient Dropouts | 1 | 2017 | 96 | 0.17 | Why? |
| Emtricitabine | 1 | 2018 | 202 | 0.17 | Why? |
| Anti-Retroviral Agents | 2 | 2018 | 1099 | 0.16 | Why? |
| Virus Latency | 1 | 2018 | 251 | 0.16 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.16 | Why? |
| Blood Component Transfusion | 1 | 2020 | 740 | 0.15 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.14 | Why? |
| Central Nervous System Diseases | 1 | 2018 | 410 | 0.12 | Why? |
| Pyrimidines | 2 | 2012 | 1557 | 0.12 | Why? |
| Safety | 1 | 2020 | 1583 | 0.12 | Why? |
| Recombination, Genetic | 1 | 2018 | 1265 | 0.11 | Why? |
| Double-Blind Method | 2 | 2017 | 5988 | 0.10 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.10 | Why? |
| Drug Resistance, Viral | 2 | 2018 | 1083 | 0.10 | Why? |
| CD4 Lymphocyte Count | 3 | 2018 | 1517 | 0.10 | Why? |
| Viral Load | 5 | 2018 | 15850 | 0.10 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.09 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.09 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.09 | Why? |
| National Institutes of Health (U.S.) | 2 | 2021 | 443 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.09 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.08 | Why? |
| Antibodies, Neutralizing | 3 | 2018 | 25288 | 0.08 | Why? |
| Herpesvirus 4, Human | 1 | 2009 | 387 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Humans | 25 | 2021 | 930598 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.07 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Epstein-Barr Virus Infections | 1 | 2009 | 366 | 0.07 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.07 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.07 | Why? |
| Lymphoma | 1 | 2009 | 522 | 0.06 | Why? |
| Delavirdine | 1 | 2002 | 5 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.06 | Why? |
| Middle Aged | 14 | 2020 | 270681 | 0.06 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.06 | Why? |
| Saquinavir | 1 | 2002 | 34 | 0.06 | Why? |
| Obesity | 2 | 2020 | 7388 | 0.06 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 533 | 0.06 | Why? |
| HIV Envelope Protein gp120 | 2 | 2017 | 267 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.06 | Why? |
| Adult | 11 | 2020 | 244371 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Female | 13 | 2021 | 380317 | 0.05 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.05 | Why? |
| Salvage Therapy | 1 | 2002 | 417 | 0.05 | Why? |
| Historically Controlled Study | 1 | 2018 | 71 | 0.05 | Why? |
| HIV Envelope Protein gp160 | 1 | 2018 | 33 | 0.05 | Why? |
| Alkynes | 1 | 2018 | 98 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Biotransformation | 1 | 2018 | 74 | 0.05 | Why? |
| Pharmacogenomic Testing | 1 | 2018 | 115 | 0.04 | Why? |
| Male | 13 | 2020 | 367725 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2021 | 481 | 0.04 | Why? |
| Adolescent | 5 | 2020 | 86841 | 0.04 | Why? |
| Binding Sites, Antibody | 1 | 2018 | 466 | 0.04 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.04 | Why? |
| Data Interpretation, Statistical | 1 | 2021 | 657 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2021 | 15421 | 0.04 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.04 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.04 | Why? |
| Aged | 7 | 2020 | 215776 | 0.04 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.04 | Why? |
| Research Design | 1 | 2012 | 5830 | 0.04 | Why? |
| Chromatography, Liquid | 1 | 2018 | 640 | 0.03 | Why? |
| CHO Cells | 1 | 2017 | 831 | 0.03 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.03 | Why? |
| Societies, Scientific | 1 | 2017 | 414 | 0.03 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 449 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2018 | 669 | 0.03 | Why? |
| Cricetulus | 1 | 2017 | 936 | 0.03 | Why? |
| Linear Models | 1 | 2020 | 1914 | 0.03 | Why? |
| Peptide Fragments | 2 | 2017 | 2075 | 0.03 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.03 | Why? |
| Advisory Committees | 1 | 2021 | 1418 | 0.03 | Why? |
| China | 1 | 2021 | 50654 | 0.03 | Why? |
| Interprofessional Relations | 1 | 2021 | 1013 | 0.03 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 386 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Clinical Trials as Topic | 1 | 2012 | 7330 | 0.03 | Why? |
| Drug Approval | 1 | 2021 | 1325 | 0.03 | Why? |
| HIV Envelope Protein gp41 | 1 | 2012 | 153 | 0.03 | Why? |
| United States | 4 | 2021 | 46150 | 0.03 | Why? |
| Virus Replication | 1 | 2012 | 14331 | 0.03 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.03 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2002 | 7268 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.02 | Why? |
| Ritonavir | 1 | 2002 | 4212 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Phylogeny | 2 | 2018 | 13341 | 0.02 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.02 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2012 | 3198 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.02 | Why? |
| United States Food and Drug Administration | 1 | 2012 | 1276 | 0.02 | Why? |
| Drug Industry | 1 | 2012 | 689 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Brain | 1 | 2020 | 5133 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.01 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.01 | Why? |
| RNA, Viral | 2 | 2017 | 32276 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| DNA, Viral | 1 | 2009 | 2521 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 9335 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Cell Line | 1 | 2012 | 12040 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Virus Internalization | 1 | 2012 | 7921 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Mutation | 1 | 2012 | 12376 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
Gulick's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(155)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(136)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_